This therapeutic concept targets integrin-mediated synaptic adhesion and focal adhesion signaling to protect neuronal connectivity in Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders. Rather than targeting protein aggregation directly, this approach preserves the structural integrity of synapses and neuronal networks by enhancing integrin-dependent adhesion mechanisms that decline with aging and neurodegeneration.
Integrin signaling is increasingly recognized as a critical regulator of synaptic stability, spine morphology, and neuronal survival.[1][2] Post-mortem studies show reduced integrin signaling in AD brains,[3] and genetic studies link integrin genes to neurodegenerative disease risk.[4] Recent advances in integrin-modulating compounds—including allosteric agonists, mechanosensitive channel openers, and integrin-targeted nanobodies—make targeted CNS intervention feasible for the first time.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | First-in-class integrin-synapse protection concept; not in clinical development |
| Mechanistic Rationale | 8 | Strong preclinical data in multiple models; integrin decline documented in AD/PD brains |
| Addresses Root Cause | 6 | Protects synaptic structure rather than clearing aggregates; addresses connectivity loss |
| Delivery Feasibility | 7 | RGD peptides can be modified for BBB penetration; nasal delivery viable |
| Safety Plausibility | 8 | Integrin agonists have acceptable safety margins; selective CNS targeting reduces risk |
| Combinability | 9 | Highly synergistic with amyloid/tau clearance, neurotrophic factors, and memantine |
| Biomarker Available | 7 | Synaptic biomarkers (neurogranin, SNAP-25) can track efficacy; FAK phosphorylation in PBMCs |
| De-risking Path | 7 | iPSC neurons with integrin knockdown available; mouse models well-characterized |
| Multi-disease Potential | 8 | AD, PD, ALS, stroke recovery, traumatic brain injury all involve integrin dysfunction |
| Patient Impact | 7 | Preserves cognition and function; complementary to disease-modifying approaches |
Total: 75/100
| Milestone | Timeline | Cost |
|---|---|---|
| Lead identification (RGD variants) | Months 1-4 | $400K |
| BBB penetration optimization | Months 3-8 | $600K |
| IND-enabling toxicity (rodent + non-rodent) | Months 6-12 | $1.2M |
| Phase 1 Total | $2.2M |
Go/No-Go: p-FAK activation in human neurons at nM concentrations; no off-target toxicity
| Milestone | Timeline | Cost |
|---|---|---|
| IND submission | Month 10 | $150K |
| Phase 1a single ascending dose | Months 12-15 | $1.5M |
| Phase 1b multiple ascending dose | Months 14-20 | $2.0M |
| Phase 2a Total | $3.65M |
Go/No-Go: Safety in 24 healthy volunteers; target engagement biomarker (p-FAK in PBMCs)
| Milestone | Timeline | Cost |
|---|---|---|
| Phase 2 randomized controlled trial | Months 18-28 | $4.5M |
| Biomarker validation | Months 20-26 | $800K |
| Regulatory interaction (FDA Type B) | Month 24 | $100K |
| Phase 2b Total | $5.4M |
Go/No-Go: Significant reduction in CSF neurogranin vs. placebo (p<0.05); acceptable safety profile
| Milestone | Timeline | Cost |
|---|---|---|
| Phase 3 registration trial (N=400) | Months 28-44 | $18M |
| CMC scale-up | Months 24-36 | $2.5M |
| NDA preparation | Months 40-48 | $1.2M |
| Phase 3 Total | $21.7M |
Total Program Cost: $32.95M over 48 months
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| BBB penetration insufficient | Medium | High | Focus on active transport; explore nasal delivery |
| Off-target integrin effects | Low | High | Selective α5β1/αvβ3 targeting; avoid αIIbβ3 |
| Lack of efficacy signal | Medium | High | Enrich for patients with high synaptic dysfunction biomarkers |
| Competition with existing approaches | Low | Medium | Position as adjunct to disease-modifying therapies |
Regeneration & Reversal — This concept falls primarily in the Regeneration & Reversal category as it aims to restore and protect synaptic connectivity rather than just halt disease progression. It complements approaches in Novel Targets (FAK/ILK signaling) and Combination Logic (synergy with other modalities).
| Disease | Relevance | Priority |
|---|---|---|
| Alzheimer's Disease | Primary — synapse loss correlates with cognitive decline; integrin signaling declines with age | High |
| Parkinson's Disease | Secondary — dopaminergic neuron survival depends on integrin signaling | Medium |
| Amyotrophic Lateral Sclerosis | Secondary — motor neuron vulnerability involves integrin dysfunction | Medium |
| Frontotemporal Dementia | Secondary — synaptic pathology in FTD | Medium |
| Stroke Recovery | High — integrin-mediated recovery | High |
Chen et al. RGDS peptide improves memory in 5xFAD mice (2020). 2020. ↩︎ ↩︎
Shi et al. αvβ3 integrin agonist protects dopaminergic neurons (2022). 2022. ↩︎ ↩︎
Wang et al. Integrin expression in AD brains (2021). 2021. ↩︎ ↩︎
Liu et al. ITGB1 polymorphisms and AD risk (2019). 2019. ↩︎ ↩︎
Wang et al. Integrin nanobodies enhance synaptic density (2023). 2023. ↩︎